Jacqueline E. Shea - Mar 11, 2023 Form 4 Insider Report for INOVIO PHARMACEUTICALS, INC. (INO)

Role
Chief Executive Officer, Director
Signature
/s/ Jacqueline E. Shea
Stock symbol
INO
Transactions as of
Mar 11, 2023
Transactions value $
-$29,357
Form type
4
Date filed
3/13/2023, 05:07 PM
Previous filing
Feb 28, 2023
Next filing
May 12, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction INO Common Stock Options Exercise +59.7K +47.01% 187K Mar 11, 2023 Direct F1
transaction INO Common Stock Tax liability -$29.4K -26K -13.91% $1.13 161K Mar 11, 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction INO Restricted Stock Unit Options Exercise $0 -59.7K -100% $0.00* 0 Mar 11, 2023 Common Stock 59.7K Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of common stock. On March 11, 2020, the reporting person was granted 179,211 restricted stock units, vesting as follows: 59,737 shares vested on March 11, 2021; 59,737 shares vested on March 11, 2022; and 59,737 shares vested on March 11, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.
F2 The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in footnote (1) herein.